Market Closed - Xetra 11:37:32 2024-05-08 am EDT After market 03:58:00 pm
9.625 EUR +0.89% Intraday chart for Evotec SE 9.603 -0.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EVOTEC : Warburg Research reiterates its Buy rating ZD
EVOTEC : RBC reiterates its Buy rating ZD
Bayer: strategic collaboration with Evotec CF
Evotec, Bayer to Collaborate on New Cardiovascular Disease Therapies MT
Evotec, Bayer to Focus on Precision Treatments for Cardiovascular Diseases MT
Bayer and Evotec Collaborate to Advance Precision Cardiology CI
EVOTEC : Deutsche Bank gives a Buy rating ZD
The specter of stagflation rears its ugly head again Our Logo
EVOTEC : Buy rating from Deutsche Bank ZD
Top Midday Decliners MT
Dpa-AFX Overview: COMPANIES from 24.04.2024 - 15:15 DP
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday MT
Transcript : Evotec SE, 2023 Earnings Call, Apr 24, 2024
Technology Stocks Gain Amid Tesla's EV Plans as US Equity Futures Turn Mostly Higher Pre-Bell MT
Sector Update: Health Care MT
Top Premarket Decliners MT
RBC upgrades Evotec to 'Outperform' after figures and outlook DP
EVOTEC : Warburg Research reaffirms its Buy rating ZD
Jefferies rates Evotec a 'Buy' after figures and outlook DP
EVOTEC : Jefferies reaffirms its Buy rating ZD
EVOTEC : RBC keeps its Buy rating ZD
Evotec crashes - Too much uncertainty DP
Evotec SE Reports Earnings Results for the Full Year Ended December 31, 2023 CI
U.S. Futures, European Stocks Mixed DJ
Evotec under pressure - outlook disappointed DP
Chart Evotec SE
More charts
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.54 EUR
Average target price
21.99 EUR
Spread / Average Target
+130.50%
Consensus
  1. Stock Market
  2. Equities
  3. EVT Stock
  4. News Evotec SE
  5. Evotec CEO to Step Down in 2026; Interim Successor Appointed
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW